6560 Kennedy Road
218 articles with Cipher Pharmaceuticals
Brinavess® (vernakalant hydrochloride) is for the rapid conversion of recent onset atrial fibrillation
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis
Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market
Canadian product revenue increased 33%
New portfolio royalty extends through December 2024
Cipher Pharmaceuticals Inc. announced the details of its Q2 2018 financial results conference call on Friday, August 10, 2018.
Dr. Gajewczyk has more than 25 years of pharmaceutical industry experience in the research, clinical development and commercialization of pharmaceutical, biologics, vaccine and medical device products.
Effective May 15, 2018, the previously announced acquisition by Cipher Pharmaceuticals Inc. ("Cipher") of the Canadian business portfolio of Cardiome Pharma Corp. was completed.
Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has completed its previously announced acquisition of Cardiome Pharma Corp.
Cardiome Pharma Corp. Becomes Correvio Pharma Corp., Closes on $25.5 million (CAD) in Non-Dilutive Capital
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today the voting results for the election of directors at its Annual and Special Meeting of Shareholders held on May 10, 2018 in Toronto, Ontario.
Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three months ended March 31, 2018.
Cipher Pharmaceuticals Inc. announced the details of its Q1 2018 financial results conference call and Annual and Special Meeting of shareholders on Thursday, May 10, 2018.
Dr. Rulleau is currently a partner at CTI Life Sciences
Cipher announced four transactions that demonstrate meaningful progress in the execution of its growth strategy to assemble a diversified portfolio of prescription products that will deliver reliable growth for shareholders.
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to U.S. FDA-Approved A-101 40% Topical Solution from Aclaris Therapeutics
Transaction broadens Cipher's Canadian dermatology portfolio with first and only prescription product for raised seborrheic keratosis.
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome
Cipher Pharmaceuticals and Cardiome Pharma Corp. announced their entry into a definitive arrangement agreement pursuant to which Cipher will acquire the Canadian business portfolio of Cardiome.
90% increase in revenue and 214% increase in income from continuing operations for Q4 2017
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE from Synergy Pharmaceuticals
TRULANCE is a once-daily tablet approved by the U.S. Food and Drug Administration for the treatment of adults with chronic idiopathic constipation and irritable bowel syndrome with constipation.